Sidley advised Viva Biotech Holdings (HKEX: 1873) (Viva Biotech) on successfully issuing US$180 million of guaranteed convertible bonds due 2025 through its wholly owned subsidiary, Viva Incubator Investment Management Limited. J.P. Morgan Securities, The Hongkong and Shanghai Banking Corporation Limited and China International Capital Corporation Hong Kong Securities Limited are the underwriters in this transaction. This project marks another milestone since Sidley successfully assisted Viva Biotech’s listing on the Main Board of The Stock Exchange of Hong Kong Limited in 2019.
Viva Biotech is a leading open-access and innovation-driven technology platform company, and has become a cradle for promising biotechnology companies through its innovative and unique business model.
The Sidley team was led by partners Mengyu Lu, Oliver Zhong and Carrie Li, with support from associate Jacob Zhao, legal managers Ashlee Wu and Paul Qu, senior legal assistant Grace Qiao and legal assistant Kaiwen Xu.
Sidley is a multidisciplinary one-stop service shop in the market for life sciences clients. We advise clients across different stages of their life cycles, ranging from formation, corporate governance and compliance operations in the start-up period, to initial public offering, refinancing and bonds/notes issues in the raising capital stage, to domestic and overseas mergers and acquisitions, asset restructuring, equity incentive plans and privatization transactions when clients expand their businesses.